Control
Sep 29 2021 |
et al., Inflammation Research, doi:10.1007/s00011-021-01507-5 | The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study |
| 70% lower ICU admission (p=0.08) and 65% greater improvement (p<0.0001). RCT 206 severe COVID-19 patients not requiring mechanical ventilation, showing higher sustained clinical improvement and lower ICU admission with levilimab. There was no difference in mortality. | ||